Cargando…

New-onset and relapsed Graves’ disease following COVID-19 vaccination: a comprehensive review of reported cases

Global Coronavir us disease 2019 (COVID-19) vaccination efforts are being intensified to combat the pandemic. As the frequency of immunization against COVID-19 has increased, some adverse effects related to vaccination have emerged. Within this context, this article reviewed 62 Graves’ disease (GD)...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Kan, Gao, Yiyang, Li, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10339579/
https://www.ncbi.nlm.nih.gov/pubmed/37443067
http://dx.doi.org/10.1186/s40001-023-01210-7
_version_ 1785071876833280000
author Chen, Kan
Gao, Yiyang
Li, Jing
author_facet Chen, Kan
Gao, Yiyang
Li, Jing
author_sort Chen, Kan
collection PubMed
description Global Coronavir us disease 2019 (COVID-19) vaccination efforts are being intensified to combat the pandemic. As the frequency of immunization against COVID-19 has increased, some adverse effects related to vaccination have emerged. Within this context, this article reviewed 62 Graves’ disease (GD) cases following COVID-19 vaccination, to probe the potential association between the vaccination and the onset of GD. A comprehensive search of the PubMed, Web of Science, and Scopus databases was conducted to collect GD cases following COVID-19 vaccination up to June 7, 2023. Among the 62 GD cases included in this review, there were 33 (53.2%) new-onset GD and 10 (16.1%) relapsed GD patients following mRNA vaccination, 14 (22.6%) new-onset GD and 4 (6.5%) relapsed GD patients following viral vector vaccination, and 1 (1.6%) relapsed GD patients following inactivated vaccination. Median durations to symptoms onset for new-onset and relapsed GD were 12 (range: 1–60) and 21 (range: 5–30) days following mRNA vaccination, while 7 (range: 1–28) and 14 (range: 10–14) days following viral vector vaccination, respectively. While the definitive pathogenesis of GD following COVID-19 vaccination remains unclear, it might be associated with cross-immune responses triggered by molecular mimicry, and an adjuvant-induced autoimmune/inflammatory syndrome. However, due to the limited number of observed GD cases following COVID-19 vaccination and the lack of systematic experimental studies, a causal relationship between COVID-19 vaccination and the onset of GD has not been definitively confirmed. It should be highlighted that most of GD patients following COVID-19 vaccination experienced positive outcomes after treatment. In the broader context of ending the COVID-19 pandemic and reducing mortality rates, the benefits of COVID-19 vaccination significantly outweigh mild risks such as treatable GD. Adherence to the COVID-19 vaccination schedule is therefore imperative in effectively managing the pandemic.
format Online
Article
Text
id pubmed-10339579
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-103395792023-07-14 New-onset and relapsed Graves’ disease following COVID-19 vaccination: a comprehensive review of reported cases Chen, Kan Gao, Yiyang Li, Jing Eur J Med Res Review Global Coronavir us disease 2019 (COVID-19) vaccination efforts are being intensified to combat the pandemic. As the frequency of immunization against COVID-19 has increased, some adverse effects related to vaccination have emerged. Within this context, this article reviewed 62 Graves’ disease (GD) cases following COVID-19 vaccination, to probe the potential association between the vaccination and the onset of GD. A comprehensive search of the PubMed, Web of Science, and Scopus databases was conducted to collect GD cases following COVID-19 vaccination up to June 7, 2023. Among the 62 GD cases included in this review, there were 33 (53.2%) new-onset GD and 10 (16.1%) relapsed GD patients following mRNA vaccination, 14 (22.6%) new-onset GD and 4 (6.5%) relapsed GD patients following viral vector vaccination, and 1 (1.6%) relapsed GD patients following inactivated vaccination. Median durations to symptoms onset for new-onset and relapsed GD were 12 (range: 1–60) and 21 (range: 5–30) days following mRNA vaccination, while 7 (range: 1–28) and 14 (range: 10–14) days following viral vector vaccination, respectively. While the definitive pathogenesis of GD following COVID-19 vaccination remains unclear, it might be associated with cross-immune responses triggered by molecular mimicry, and an adjuvant-induced autoimmune/inflammatory syndrome. However, due to the limited number of observed GD cases following COVID-19 vaccination and the lack of systematic experimental studies, a causal relationship between COVID-19 vaccination and the onset of GD has not been definitively confirmed. It should be highlighted that most of GD patients following COVID-19 vaccination experienced positive outcomes after treatment. In the broader context of ending the COVID-19 pandemic and reducing mortality rates, the benefits of COVID-19 vaccination significantly outweigh mild risks such as treatable GD. Adherence to the COVID-19 vaccination schedule is therefore imperative in effectively managing the pandemic. BioMed Central 2023-07-13 /pmc/articles/PMC10339579/ /pubmed/37443067 http://dx.doi.org/10.1186/s40001-023-01210-7 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Chen, Kan
Gao, Yiyang
Li, Jing
New-onset and relapsed Graves’ disease following COVID-19 vaccination: a comprehensive review of reported cases
title New-onset and relapsed Graves’ disease following COVID-19 vaccination: a comprehensive review of reported cases
title_full New-onset and relapsed Graves’ disease following COVID-19 vaccination: a comprehensive review of reported cases
title_fullStr New-onset and relapsed Graves’ disease following COVID-19 vaccination: a comprehensive review of reported cases
title_full_unstemmed New-onset and relapsed Graves’ disease following COVID-19 vaccination: a comprehensive review of reported cases
title_short New-onset and relapsed Graves’ disease following COVID-19 vaccination: a comprehensive review of reported cases
title_sort new-onset and relapsed graves’ disease following covid-19 vaccination: a comprehensive review of reported cases
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10339579/
https://www.ncbi.nlm.nih.gov/pubmed/37443067
http://dx.doi.org/10.1186/s40001-023-01210-7
work_keys_str_mv AT chenkan newonsetandrelapsedgravesdiseasefollowingcovid19vaccinationacomprehensivereviewofreportedcases
AT gaoyiyang newonsetandrelapsedgravesdiseasefollowingcovid19vaccinationacomprehensivereviewofreportedcases
AT lijing newonsetandrelapsedgravesdiseasefollowingcovid19vaccinationacomprehensivereviewofreportedcases